Niedzialkowska Ewelina, Steafo Lark, Alsabti Sam, Kim Alice
Department of Internal Medicine, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, USA.
Division of Endocrinology, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, USA.
Proc (Bayl Univ Med Cent). 2024 Oct 11;38(2):199-201. doi: 10.1080/08998280.2024.2413320. eCollection 2025.
Immune checkpoint inhibitors (ICIs) are novel treatment modalities that have revolutionized the field of oncology. Their widespread use in various cancers and prolonged survival of patients led to the identification of a wide range of side effects associated with the therapy, known as immune-related adverse effects (irAEs). IrAEs are presumed to arise from immunologic enhancement and frequently result in endocrine disorders. Thyroid dysfunction is not uncommon during therapy with pembrolizumab and affects up to 13% to 14% of patients. Thyroid storm associated with ICIs is extremely rare. We present a case of a 34-year-old woman with metastatic ovarian carcinoma who developed thyroid storm shortly after an addition of pembrolizumab.
免疫检查点抑制剂（ICIs）是彻底改变肿瘤学领域的新型治疗方式。它们在各种癌症中的广泛应用以及患者生存期的延长，导致人们发现了与该疗法相关的一系列副作用，即免疫相关不良反应（irAEs）。irAEs被认为是由免疫增强引起的，并且经常导致内分泌紊乱。在使用帕博利珠单抗治疗期间，甲状腺功能障碍并不罕见，影响多达13%至14%的患者。与ICIs相关的甲状腺风暴极为罕见。我们报告一例34岁转移性卵巢癌女性患者，在加用帕博利珠单抗后不久发生甲状腺风暴。
